Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Addressing CAR-NK unknowns

Hermann Einsele • 7 Dec 2021
ASH 2021
Multiple Myeloma CAR-T

Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, highlights unanswered questions regarding the clinical utility of CAR-NK cells for the treatment of multiple myeloma. While CAR-NK appears to be a promising strategy that could be safer and faster than current CAR-T therapies, it is unclear whether cell migration and persistence are comparable. Investigations into these important questions are ongoing. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Hermann Einsele

2:44
Moving CAR-T into earlier lines of therapy in multiple myeloma
Hermann Einsele • 17 Feb 2024
0:45
CAR T-cell therapy in lenalidomide-refractory multiple myeloma
Hermann Einsele • 17 Feb 2024
1:19
Sequencing bispecific antibodies and CAR-T therapy & the evolving role of bispecifics in myeloma
Hermann Einsele • 26 Jun 2023
8:16
Results from CARTITUDE-4: cilta-cel for lenalidomide-refractory multiple myeloma
Hermann Einsele • 26 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals